Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.

ABSTRACT:

Importance

Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease. The associations of these 2 oral antiviral drugs with hospitalization and death resulting from infection with new SARS-CoV-2 Omicron subvariants, particularly BQ.1.1 and XBB.1.5, are unknown.

Objective

To assess the association of nirmatrelvir or molnupiravir use with the risks of hospitalization and death among patients infected with new Omicron subvariants.

Design, setting, and participants

This was a cohort study of patients who received a diagnosis of COVID-19 at Cleveland Clinic from April 1, 2022, to February 20, 2023 (during

SUBMITTER: Lin DY 

PROVIDER: S-EPMC10514733 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature